Crohn's Disease Clinical Trials

• Has CD or fistulizing Crohn's Disease (CD) of at least 12 weeks' duration, with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, and/or endoscopy

• Have moderately to severely active CD, defined as baseline Crohn's Disease Activity Index (CDAI) score greater than or equal to (\>=) 220 but less than or equal to (\<=) 450

• Baseline endoscopic evidence of active ileal and/or colonic CD as assessed by central endoscopy reading at the screening endoscopy defined as a screening Simple Endoscopic Score for Crohn's Disease (SES CD) \>= 4 (for participants with isolated ileal disease) or \>= 6 (for participants with colonic or ileocolonic disease), based on the presence of ulceration in any 1 of the 5 ileocolonic segments, resulting in the following specified ulceration component scores:

‣ a minimum score of 1 for the component of size of ulcers AND

⁃ a minimum score of 1 for the component of ulcerated surface

• In the opinion of the investigator, participant's disease is appropriate to treat with the maintenance dosing regimens utilized in the study

• Adhere to the requirements for concomitant medications for the treatment of CD as mentioned in the protocol